A multidisciplinary team of experts has released a joint consensus document on the role of F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.
The American Society of Nuclear Cardiology and the Society of Nuclear Medicine and Molecular Imaging collaborated on the project.
The effort was spurred by the realization that randomized prospective clinical trials were not feasible for this rare disease. Experts in cardiovascular imaging, clinical cardiology, cardiac electrophysiology and systemic sarcoidosis contributed to the document, which is being jointly published in the Journal of Nuclear Cardiology and The Journal of Nuclear Medicine.
“This document is unique in providing not only a consensus on the current indications for performing FDG PET/CT for the detection of cardiac sarcoidosis and monitoring therapy and recommendations on image acquisition, processing, and interpretation, but also discusses the current considerations in the management and treatment of cardiac sarcoidosis,” lead author Panithaya Chareonthaitawee, MD, of the Mayo Clinic’s department of cardiovascular medicine, said in a statement. “The importance of assessing for extracardiac sarcoidosis is also emphasized in this document, with a focus on the interpretation of extracardiac PET/CT in the context of cardiac sarcoidosis evaluation."
The full joint consensus statement is available below:
Daniel joined TriMed’s Chicago editorial team in 2017 as a Cardiovascular Business writer. He previously worked as a writer for daily newspapers in North Dakota and Indiana.